Key result
Patiromer is an effective and well-tolerated oral potassium binder for treating hyperkalemia, which may improve disease state outcomes when combined with RAAS inhibitors.
Why the study?
Hyperkalemia remains difficult to control in chronic kidney disease, heart failure, and diabetes, prompting review of clinical trials, real-world data, and combination with RAASi using the oral potassium binder patiromer.
Does patiromer improve outcomes, safety, and tolerability in patients with hyperkalemia associated with chronic kidney disease, heart failure, and diabetes?
Does patiromer improve outcomes, safety, and tolerability in patients with hyperkalemia associated with chronic kidney disease, heart failure, and diabetes?
This review highlights the efficacy and safety of patiromer for managing hyperkalemia, particularly its role in enabling RAAS inhibitor therapy in vulnerable populations.
May improve hyperkalemia control in CKD, HF, and diabetes; leaves open long-term outcomes and optimal dosing.
Hyperkalemia remains one of the most difficult consequences of disease state and treatment for patients with chronic kidney disease, heart failure, and diabetes. Controlling hyperkalemia can be difficult, but has become easier with the introduction of novel oral potassium binders. Patiromer was approved in 2015 for the treatment of hyperkalemia by the FDA in the United States. Several pivotal trials proved its efficacy, safety, and improved tolerability compared with previous hyperkalemia treatments. Additionally, many real-world publications and trials have given deeper insights into the capabilities of patiromer. We discuss improved disease state outcomes with combining patiromer with RAASi. This paper will also highlight new trials forthcoming that are highly anticipated to expand the possibilities in using patiromer to improve outcomes and populations.
No takes yet. Share an insight, caveat, or question.
Colbert et al. (2022) conducted a review in Hyperkalemia. Patiromer was evaluated. Patiromer is an effective and well-tolerated oral potassium binder for treating hyperkalemia, which may improve disease state outcomes when combined with RAAS inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: